Full Press Release Details
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia.
REGN
Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia
Key Takeaway: Regeneron and Bayer Initiate Phase 3 Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Asia and Russia